Compare Dow Inc (DOW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Dow Inc trades at $28.42 (market cap $20.65B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Dow Inc is far larger — about 2× State Street SPDR S&P Biotech ETF's market cap, and Dow Inc pays a 4.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DOW | XBI | |
|---|---|---|
Market Cap | $20.65B | $10.11B |
Volume | 14,126,943 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $41.87 | $169.55 |
52-Week Low | $20.65 | $104.99 |
Typical Hold Time | 82 Days | 38 Days |
Enterprise Value | $36.34B | — |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.59, up 2.95% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite mixed indicators, with recent earnings beats in Q4 2025 through Q2 2026. However, fundamentals are weak, with a negative net income margin of -3.13% in 2025 and declining revenue from $56.9B in 2022 to $40.0B in 2025. Cash flow trends improved in 2025, but debt-to-asset ratios have risen to 29.87%.
The outlook is cautious; while analyst consensus is a buy with a $34.22 target, high valuation (P/E 75.93) and profitability challenges pose risks. Opportunities include dividend stability and potential margin recovery, but investors face headwinds from cyclical demand and competitive pressures in the chemicals sector.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
